Alfuprost MP tabs 10mg #30

Alfuprost MP instruction for use

You can buy Alfuprost MP here

Composition

Each tablet of prolonged action contains:
active ingredient: alfuzosin hydrochloride 10 mg.
excipients: anhydrous lactose 77 mg, magnesium stearate 2.5 mg, colloidal silicon dioxide 3 mg, povidone (PVP - K 30) 15 mg, talc 2.5 mg, hypromellose 85 mg, hyprolosis 155 mg.
Packaging - 30 pieces

pharmachologic effect

Pharmacodynamics

Alfuzosin is a quinazoline derivative that is active when taken orally. This is a selective antagonist of postsynaptic alpha-1 -adrenoreceptors. In vitro pharmacological tests showed the selectivity of alfuzosin on alpha-1 receptors located in the prostate gland, at the bottom of the bladder and in the prostate part of the urethra. As a result of direct effects on the smooth muscles of the tissues of the prostate gland, alpha-1-adrenoblockers reduce the resistance to urine outflow.
Alfuzosin improves urination parameters, reducing the tone of the urethra and resistance to outflow from the bladder, facilitating the emptying of the bladder. Alfuzosin in patients with benign prostatic hyperplasia achieves:
    a significant increase in the maximum flow rate (Qmax) by an average of 30% in patients with Qmax ≤ 15 ml / s. This improvement was observed starting from the first dose;
    a significant decrease in resistance to urine flow and an increase in the volume of urine excreted
    significant decrease in residual urine volume.

Pharmacokinetics

absorption: the average relative bioavailability is 104.4% compared with the immediate release form (2.5 mg twice a day) in healthy middle-aged volunteers, and the maximum plasma concentration is reached 9 hours after taking alfuzosin, compared to 1 hour for an immediate release form.
The half-life of alfuzosin is 9.1 hours. Studies have shown that the area under the concentration-time curve when taking alfuzosin after a meal is comparable to the results of taking alfuzosin before a meal, therefore the meal does not affect the pharmacokinetic profile of Alfuprost MP. Compared with healthy middle-aged volunteers, elderly patients do not increase pharmacokinetic parameters.
Compared with persons with normal renal function, the average values ​​of the maximum concentration of the area under the "concentration-time" curve in patients with renal insufficiency are moderately increased, without changing the half-life. This change in the pharmacokinetic profile of alfuzosin is not considered to have clinical significance, and therefore it does not require a dose adjustment.
metabolism: binding of alfuzosin to plasma proteins is about 90%. Alfuzosin is almost completely metabolized in the liver.
elimination: only 11% of alfuzosin is unchanged in the urine. Most of the metabolites (which are not active) are excreted in the feces (75-90%).
The pharmacokinetic profile of alfuzosin does not change in chronic heart failure.

Alfuprost MP, indications for use

Treatment of functional manifestations of benign prostatic hyperplasia in the absence of the possibility of surgical intervention, as well as in cases of progressive growth, especially in elderly patients.

Contraindications

    Hypersensitivity to alfuzosin and / or other components of the drug Alfuprost MP.
    Orthostatic hypotension.
    Severe abnormal liver function.
    Severe renal failure (creatinine clearance less than 30 ml / min).
    Congenital lactase deficiency, lactose intolerance, glucose-galactose malabsorption.

Dosage and administration

Inside - 2.5 mg 3 times / day. For patients older than 65 years old - the initial dose is 2.5 mg 2 times / day (in the morning and in the evening); further, the dose may be increased (but not more than 10 mg / day).

Use during pregnancy and lactation

The drug Alfuprost MP is not intended for use in women.

Side effects of Alfuprost MP

On the part of the digestive system: epigastric pain, nausea, diarrhea; rarely, dry mouth.
From the side of the central nervous system: dizziness, headache; rarely - drowsiness.
Since the cardiovascular system: rarely - tachycardia, orthostatic hypotension.
Allergic reactions: rarely - skin rash, itching.
Others: discomfort; rarely - swelling, pain behind the sternum.

special instructions for Alfuprost MP

In some individuals, especially in patients receiving antihypertensive treatment, postural hypotension, with or without symptoms (dizziness, fatigue, sweating), may develop within a few hours after taking Alfuzosin, as with other alpha-1 -blockers. In such cases, the patient must lie until the symptoms disappear. These phenomena are usually temporary, occur at the beginning of treatment and usually do not affect the continuation of treatment. The patient should be warned about the possibility of such phenomena.
Patients with coronary insufficiency should not be prescribed alfuzosin in monotherapy. It is necessary to continue the treatment of coronary insufficiency. If angina returns or worsens, treatment with alfuzosin should be discontinued. Patients should be warned that tablets should be swallowed whole. Tablets should not be cracked, chewed, crushed or ground into powder. These actions can lead to inappropriate release and absorption of the active substance and, consequently, to side effects that can quickly develop. The particular risk is associated with the start of treatment, when phenomena such as dizziness, visual disturbances and asthenia can be observed. This should be taken into account when performing potentially hazardous activities that require special attention and quick reactions (driving and other vehicles, working with moving machinery, the work of the dispatcher and operator, etc.).

Interaction

Not recommended combinations:
Alfuprost MP with alpha-1 receptor blockers (prazosin, urapidil, minoxidil): increased hypotensive effect, the risk of severe postural hypotension.
Combinations to be taken into account:
Alfuprost MP with antihypertensive drugs: increased hypotensive effect and the risk of postural hypotension (additive effect). With CYP3A4 isoenzyme inhibitors (ketoconazole, itraconazole, ritonavir): an increase in the concentration of alfuzosin in the blood.

Overdose

Symptoms: decrease in blood pressure.
In case of overdose, the patient should be hospitalized, be in the "lying" position. Symptomatic treatment of hypotension (administration of vasoconstrictor agents and plasma substitutes (to increase circulating blood volume)) should be carried out. Dialysis is ineffective due to the high degree of binding of alfuzosin to proteins.
Shelf life - 3 years.

Storage conditions

In a dry place, at a temperature not higher than 25 ° C.

Terms of sell

You can buy Alfuprost MP without a prescription.